I received my PhD with Cum Laude from the Netherlands Cancer Institute, defining a novel mode of action of a broadly used anti-cancer drug, doxorubicin, and its anthracycline members. I discovered that doxorubicin and other anthracycline members can also destabilize nucleosomes and evict histones from particular chromatin regions upon intercalating into the chromatin. As a result, DNA damage response is attenuated and the epigenome of the cell is deregulated. After brief period of post-doc training at the Netherlands Cancer Institute, I moved to the Department of Genetics, Stanford University in the US, where I developed unique genome-wide screen systems to study the function of the non-coding genome. In 2018 I started my research group at the Department of Cell and Chemical Biology. I was awarded the Antoni van Leeuwenhoek Prize from NKI-AvL, the Academic Excellence Award from China, Gisela Thier Fellowship, and KWF/Alpe Young lnvestigator Grant.
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.
Pang B*, Qiao X*, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W and Neefjes J.
Nature Communications. 2013;4:1908
Chemical profiling of the genome with anti-cancer drugs defines target specificities.
Pang B*†, de Jong J*, Qiao X*, Wessels LFA†, Neefjes J†.
Nature Chemical Biology. 2015, 11, 472–480.
Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer.
Wijdeven R*, Pang B*, van der Zanden S, Qiao X, Blomen V, Hoogstraat M, Lips EH, Janssen J, Wessels LFA, Brummelkamp T, Neefjes J.
Cancer Research. 75(19) October 1, 2015.